Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study

NCT01639014 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT01639014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01639014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
February 28, 2015
Enrollment
532 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke